SecBot SecBot
SECBOTREPLAY Home › Report › CYTK

CYTK · Cytokinetics released a corporate presentation updating on commercial…

CYTOKINETICS INC · 8-K filed May 5, 2026 at 16:12 ET

At the news

NEUTRALIMPACT 3/10

8-K filed May 5, 2026 at 16:12 ET

Cytokinetics released a corporate presentation updating on commercial launch progress of MYQORZO (aficamten) for oHCM, positive ACACIA-HCM trial results for nHCM, and pipeline advancement. The filing is routine with no new material events or financial disclosures beyond previously announced data and launch metrics.

  • Cash, cash equivalents and investments of approximately $1.1B as of 3/31/26
  • MYQORZO launched in U.S. and China in January 2026; EU approval secured
  • 680 patients prescribed MYQORZO as of 3/31/26, growing to 1,100 as of 4/30/26
  • 1,400+ REMS-certified HCPs as of 3/31/26; average 2.4 prescriptions per HCP

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access